Liver fibrosis arises when chronic injury from viral hepatitis, alcohol, fatty liver disease, or other insults pushes hepatic stellate cells into an activated, myofibroblast-like state. In their quiescent form, these cells store vitamin A and quietly regulate blood flow through the liver’s sinusoids. When activated, they proliferate, migrate, and deposit extracellular matrix faster than it can be degraded, gradually choking the organ’s architecture into the stiff, nodular tissue of cirrhosis. Despite decades of research, no approved therapy reverses established fibrosis; treatment has largely meant removing the underlying cause and hoping the liver’s own regenerative capacity keeps pace. Praziquantel had already shown hints of anti-fibrotic activity in experimental settings, but how a drug best known for paralyzing schistosome worms could calm scar-forming liver cells remained a mystery.

To crack that mystery, the research team, led by Zhongkui Lu and Guoying Zhang of Nanjing Integrated Traditional Chinese and Western Medicine Hospital affiliated with Nanjing University of Chinese Medicine, together with colleagues at Xuzhou Medical University and Jinling Hospital, assembled potential praziquantel targets from public pharmacological databases and cross-referenced them against genes implicated in liver fibrosis. The overlap yielded 137 candidate genes. Enrichment analyses of this set pointed toward pathways involving xenobiotic metabolism and neuroactive ligand-receptor interactions, a signature consistent with the drug’s known pharmacology but also hinting at receptor-mediated effects beyond simple parasite membrane disruption.

The next step was to find the critical nodes within this network. Using the STRING database to construct a protein-protein interaction map and Cytoscape to visualize and prune it, the researchers identified six hub genes at the center of the praziquantel-fibrosis intersection: EGFR, ALB, TP53, PTGS2, ESR1, and CYP3A4. These genes span a striking range of functions, from growth factor signaling and tumor suppression to drug metabolism and hormone reception. But which of them actually matters causally for fibrosis, rather than merely being correlated with it? To answer that question, the team turned to Mendelian randomization, a statistical technique that uses naturally occurring genetic variants as instruments to test whether an exposure, here the expression or function of a candidate gene, has a causal effect on an outcome.

The Mendelian randomization analysis delivered a clear verdict for one gene. ESR1, the estrogen receptor alpha gene, showed genetically supported evidence of a protective causal role against liver fibrosis. A colocalization analysis, which tests whether the same genetic variant drives both the gene signal and the disease association in a genomic region, nominated a specific variant, rs3020404, as a plausible functional basis for the link. In other words, the population genetics did not merely suggest that ESR1 expression tracks with fibrosis severity; it suggested that inherited differences in ESR1 activity genuinely shift fibrosis risk, making the receptor a credible therapeutic target rather than a bystander.

Genetic plausibility still needed a physical mechanism, and for that the researchers turned to molecular modeling. Molecular docking placed praziquantel within ESR1’s ligand-binding pocket, and molecular dynamics simulations confirmed that the drug-receptor complex remains stable over simulated time, with the small molecule maintaining consistent contacts with the receptor. The modeling cannot prove binding in a living cell on its own, but it established that praziquantel and ESR1 are chemically compatible partners, setting the stage for functional tests.

The most revealing layer of the study came from single-cell RNA sequencing of liver tissue. Analyzing the data with the Seurat framework, the researchers mapped ESR1 expression across the liver’s cellular ecosystem and found it broadly present, but with a telling pattern: quiescent hepatic stellate cells and a cytokine-producing stellate cell subset, dubbed cyHSCs, expressed significantly higher levels of ESR1 than activated myofibroblastic stellate cells, or myHSCs. The receptor that praziquantel appears to target is most abundant precisely in the cell states that fibrosis threatens to destroy or corrupt, suggesting the drug may act by reinforcing the quiescent, non-fibrogenic identity of these cells.

To probe what ESR1 actually does inside stellate cells, the team ran virtual knockout experiments using scTenifoldKnk, a computational method that predicts how silencing a gene rewires a single-cell gene regulatory network. Removing ESR1 in silico disrupted a network whose most prominent casualties included RXFP1, EGFLAM, and several mitochondrial genome components such as MT-CO1, MT-CO2, and MT-ND4L. Pathway analysis of the perturbed genes showed strong enrichment in oxidative phosphorylation and immune signaling, including T cell receptor signaling. The picture that emerges is of ESR1 as an orchestrator of mitochondrial metabolic homeostasis and immunoregulatory signaling in stellate cells; when it is lost, the cells’ energy metabolism falters and inflammatory programs gain ground, conditions that favor fibrogenic activation.

Computational predictions, however convincing, demand wet-lab confirmation, and the researchers provided it. Working with LX-2 cells, a widely used human hepatic stellate cell line, they silenced ESR1 and tested whether praziquantel could still exert its anti-fibrotic effects. It could not, at least not fully. The loss-of-function experiments confirmed that ESR1 is functionally required for the drug’s benefit, closing the loop between network prediction, genetic causality, structural modeling, and cellular mechanism. The authors propose that praziquantel activates ESR1, which in turn maintains a protective gene network preserving mitochondrial function and immune balance in stellate cells, thereby blocking their transition into collagen-secreting myofibroblasts.

The implications extend well beyond one drug and one receptor. Repurposing praziquantel, whose safety profile is established through mass administration programs across the tropics, could dramatically shorten the path to clinical testing for an anti-fibrotic indication compared with developing a novel molecule from scratch. More broadly, the study showcases an integrative strategy, combining network pharmacology, Mendelian randomization, colocalization, molecular dynamics, single-cell transcriptomics, virtual knockout, and in vitro validation, that can elevate a computational hypothesis to a mechanistically grounded candidate therapy. ESR1 modulation itself may prove a fruitful therapeutic direction independent of praziquantel, and the identification of rs3020404 as a candidate functional variant offers a genetic handle for stratifying patients most likely to benefit. Much work remains: the findings rest heavily on human cell lines and public datasets, and animal models and clinical trials will be needed to confirm that the mechanism operates in scarred livers in living patients. But the study reframes a familiar antiparasitic as a plausible antifibrotic and hands hepatology a genetically validated, druggable target at the heart of the stellate cell’s decision to scar or stay quiet.

Subject of Research: Network pharmacology and experimental validation identifying ESR1 as the target through which praziquantel alleviates liver fibrosis

Article Title: Praziquantel targeting ESR1 to alleviate liver fibrosis: a comprehensive network analysis insight

Article References: Lu, Z., Kong, D., He, F., Lv, H., Guo, Y., Xia, X., & Zhang, G. (2026). Praziquantel targeting ESR1 to alleviate liver fibrosis: a comprehensive network analysis insight. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08941-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08941-1

Keywords: praziquantel, liver fibrosis, ESR1, hepatic stellate cells, Mendelian randomization, molecular docking, single-cell RNA sequencing, drug repurposing, mitochondrial function, hepatology, gene regulatory network, LX-2 cells

The study, published in the journal iScience, centers on the tricarboxylic acid (TCA) cycle, the revolving sequence of reactions that sits at the heart of mitochondrial energy production. Skeletal muscle is an energy-hungry tissue, and during sustained activity it depends overwhelmingly on oxidative phosphorylation and the TCA cycle to convert carbohydrates and fatty acids into adenosine triphosphate, the universal currency of cellular work. When these pathways falter, as they do in insulin resistance and type 2 diabetes, muscle loses its metabolic flexibility and struggles to oxidize substrates efficiently. Muscle is also remarkably adaptable, rewiring its energetic pathways within moments when exercise load surges, which makes its metabolic control points attractive therapeutic targets. Yet measuring the cycle’s throughput inside an intact organism has long been a stubborn technical problem. Established clinical tools such as phosphorus magnetic resonance spectroscopy and oxygen respirometry deliver bulk information about phosphate metabolites or whole-body energetics, but they cannot resolve the substrate-specific fluxes flowing through individual mitochondrial enzymes.

The new method belongs to a family of techniques known as hyperpolarized carbon-13 magnetic resonance spectroscopy. In hyperpolarization, a sample is cooled to near absolute zero inside a strong magnetic field, where a radical-mediated process called dynamic nuclear polarization aligns the spins of carbon-13 nuclei to a degree millions of times beyond their ordinary thermal equilibrium. When the polarized agent is rapidly dissolved and injected into the bloodstream, an MRI scanner can watch it transform into downstream metabolites, second by second. The field’s workhorse probe, [1-13C]pyruvate, has already reached human clinics and can gauge pyruvate dehydrogenase, or PDH—the gatekeeping enzyme that ushers pyruvate into the mitochondrion—by watching the labeled carbon wash into bicarbonate. But that readout carries an inherent blind spot: once the label is released as bicarbonate, it vanishes from view, leaving acetyl-coenzyme A and everything downstream of PDH invisible. Researchers have long equated PDH flux with TCA cycle flux, but the assumption had never been validated, because the standard tracer simply cannot see past the gate.

In principle, [2-13C]pyruvate solves the problem. Its labeled carbon survives PDH catalysis, rides into acetyl-CoA and propagates through the TCA cycle, ultimately tagging glutamate, a reliable signature of cycle activity. The obstacle is physics. The carbon-2 nucleus of pyruvate has a spin-lattice relaxation time, or T1, of roughly 39 seconds at 3 tesla, compared with about 67 seconds for [1-13C]pyruvate. Hyperpolarized signal decays exponentially, so a shorter T1 means the enhanced nuclear alignment drains away before the tracer ever reaches the mitochondrion, drowning the glutamate signal in noise—especially in resting muscle, where PDH flux is low. The team, led by Jae Mo Park, overcame this with two maneuvers. They replaced the three hydrogen atoms on pyruvate’s methyl group with deuterium, suppressing the dipolar and scalar interactions with neighboring protons that accelerate relaxation, and they dissolved the polarized substrate in deuterium oxide—heavy water—rather than ordinary water. Together these steps extend the T1 of the carbonyl carbon enough that [5-13C]glutamate becomes reliably detectable in living skeletal muscle even at rest, something the undeuterated tracer could only achieve in drug-stimulated tissue.

To put the probe through its paces, the researchers injected healthy Sprague-Dawley rats with hyperpolarized [2-13C,3-2H3]pyruvate twice: once at baseline and again 45 minutes after administering dichloroacetate, a drug that jolts PDH into action by blocking pyruvate dehydrogenase kinase, the enzyme that normally brakes PDH. Each tracer dose was polarized for three to four hours at 0.8 kelvin inside a dynamic nuclear polarization device, dissolved in superheated heavy water and delivered through a tail-vein catheter. Using a clinical 3 tesla MRI scanner fitted with a custom carbon-13 surface coil placed over the quadriceps, the team recorded spectra every three seconds across a 90-second window, normalizing every metabolite to the total hyperpolarized carbon-13 signal. The results were decisive. Glutamate labeled at its fifth carbon rose from 0.0116 to 0.0196 after dichloroacetate—an increase of roughly 78 percent—confirming that TCA cycle activity had accelerated. Lactate production, by contrast, barely moved, indicating the drug was acting on mitochondrial oxidation rather than on the cytosolic handling of pyruvate.

The surprise came from a second metabolite. Acetyl-L-carnitine, the ester through which the enzyme carnitine acetyltransferase parks excess acetyl groups in a cellular reservoir, surged far more dramatically: from 0.0330 to 0.1277, a leap of more than 400 percent. In other words, throwing open the mitochondrial gate did not proportionally speed up the Krebs wheel. The ratio of glutamate to the combined glutamate-plus-acetylcarnitine signal—a proxy for the balance between TCA cycle flux and PDH flux—fell by roughly 45 percent after treatment. The mitochondria were receiving acetyl-CoA far faster than they were oxidizing it, and they responded by stashing the surplus in the acetylcarnitine pool. Time-to-peak analysis confirmed the shift was not an artifact of altered perfusion: the labeled acetylcarnitine appeared no later than before, only in far greater quantity, while lactate kinetics stayed flat. Surplus acetyl units, it seems, are not wasted but banked—reversible storage that smooths the fuel supply for future bursts of demand.

This observation speaks directly to what biochemists call the acetyl-L-carnitine overflow pool hypothesis. Acetyl-CoA stands at a metabolic crossroads: when oxidative demand is high, it is fed to citrate synthase and into the TCA cycle; when demand lags, carnitine acetyltransferase converts it into acetylcarnitine for storage, ready to be remobilized when energy needs spike. Earlier work in perfused hearts established acetylcarnitine as such a reservoir, and hyperpolarized studies there showed acetylcarnitine production rising when PDH was chemically activated but staying near baseline when cardiac workload was raised with dobutamine—hinting that the buffer tracks fuel surplus rather than sheer demand. But watching that dynamic unfold in intact, resting skeletal muscle in vivo is new. The team’s data suggest that pharmacological PDH activation preferentially routes acetyl groups into the buffer rather than into accelerated oxidation, which means that measuring PDH flux alone, as the conventional bicarbonate-based approach does, could substantially overestimate the muscle’s true oxidative throughput. Human studies lend the idea physiological weight: obese individuals show reduced muscle acetylcarnitine and slower phosphocreatine recovery after exercise, while reduced carnitine acetyltransferase activity has been linked to metabolic inflexibility and insulin resistance.

Because hyperpolarized signals are fleeting and detection is demanding, the researchers validated their imaging findings with an independent method. A separate cohort of rats received a bolus of uniformly carbon-13-labeled pyruvate, and 90 seconds later their hamstring muscles were flash-frozen for gas chromatography–mass spectrometry. This ex vivo isotopomer analysis told the same story: doubly labeled glutamate, an unambiguous fingerprint of pyruvate-derived acetyl-CoA entering the cycle, roughly quadrupled in abundance in drug-treated muscle, and its concentration climbed from about 14 to 91 nanomoles per gram of tissue. The team also traced how the two-carbon label propagated across successive TCA intermediates—citrate, alpha-ketoglutarate, succinate, fumarate and malate. Fitting an exponential decay model to the pattern yielded propagation constants of 1.01 in controls versus 1.51 in treated animals, quantitative evidence of accelerated cycle flux. The labeling patterns simultaneously showed that pyruvate carboxylase, an auxiliary enzyme that could otherwise confound the analysis, contributed relatively little under these conditions.

The two techniques also diverged in instructive ways, and reconciling them clarifies what each actually measures. Hyperpolarized spectroscopy captures real-time kinetics over the first minutes after injection, whereas mass spectrometry provides a single endpoint snapshot; the acetylcarnitine pool equilibrates so quickly that a 90-second measurement understates its turnover, while glutamate labeling remains far from isotopic steady state at that moment. The study has caveats, too: the experiments involved only adult male rats, the TCA cycle activity being measured reflects pyruvate-derived carbon entry rather than total cycle turnover—fatty acids, ketone bodies and amino acids also feed the wheel—and even with the prolonged relaxation time, tracking the glutamate signal dynamically remained at the edge of detectability. The authors also note that alanine concentrations fell after dichloroacetate treatment, consistent with earlier findings that the drug suppresses cytosolic transamination of pyruvate, which reinforces confidence in the broader metabolic picture.

The implications reach well beyond basic physiology. Dichloroacetate has been investigated for decades as a treatment for mitochondrial disorders, lactic acidosis and certain cancers, because activating PDH pushes glucose toward oxidation and suppresses lactate accumulation. But the metabolic consequences of pushing more carbon through PDH likely depend on where the respiratory chain or the cycle itself is impaired, and clinicians currently lack tools that distinguish successful reactivation from futile overflow into storage. A probe that can simultaneously interrogate PDH flux, acetyl-CoA buffering and TCA turnover in the same living tissue could pinpoint bottlenecks distal to PDH and reveal whether an intervention genuinely restores oxidative capacity. The method also integrates readily with proton and phosphorus spectroscopy, opening the door to richer, multi-nuclear portraits of muscle energetics. With hyperpolarized carbon-13 pyruvate already carrying an established safety profile across multi-center human trials, the researchers argue that their deuterated carbon-2 version holds translational potential for studying exercise physiology, obesity and diabetes—conditions in which impaired metabolic flexibility and mishandled acetyl-CoA are defining features. For the first time, scientists can watch a mitochondrion deciding whether to burn its fuel—or bank it.

A central message in the article is that TERT’s influence can extend beyond its canonical telomere role. Mechanistically, TERT has been proposed to intersect with cellular stress responses and metabolic programs, contributing to more resilient mitochondrial function. It also appears capable of affecting chromatin-associated processes, potentially altering how genes governing aging-related phenotypes are expressed over time. These noncanonical effects could help explain why telomerase-linked interventions sometimes produce broad, multi-system improvements rather than purely chromosome-end protection.

Translational strategies, the Perspective notes, are increasingly focused on restoring TERT activity toward physiological levels rather than forcing maximal telomerase expression. In mouse studies and human cell models, re-establishing TERT expression in ranges characteristic of younger biology—and related telomere-targeted approaches—has been associated with improvements in selected age-associated phenotypes. Importantly for the field, these gains have often been reported without a detectable increase in cancer, a key consideration for any geroprotective approach.

At the same time, human genetics introduces a caution flag. Common genetic variation in the TERT locus is linked with higher risk for several cancers, reinforcing that manipulating TERT is not a purely “anti-aging” switch. The Perspective argues that mechanistic studies must clarify how different TERT states—levels, localization, and downstream partners—translate into both tissue rejuvenation and tumorigenic risk.

The author places emphasis on long-term safety evaluation and careful therapeutic design. Because cancer risk may depend on context, cell type, and duration of TERT modulation, interventions likely require fine-tuned dosing, temporal control, and rigorous monitoring. “Cautious therapeutic framework” is the guiding theme: demonstrate geroprotective signals, characterize telomere and non-telomere biology, and stress-test for oncogenic outcomes.

Ultimately, the Perspective suggests that TERT occupies an influential position in aging biology with plausible leverage over healthspan. But turning that promise into a real therapy will demand durability of benefits, mechanistic clarity, and a safety case robust enough to withstand years—not months—of follow-up.

Subject of Research: TERT as an upstream regulator of aging and a candidate target for geroprotective therapies

Article Title: Positioning TERT at the apex of aging

Article References: DePinho, R.A. Positioning TERT at the apex of aging. Nat Aging (2026). https://doi.org/10.1038/s43587-026-01179-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s43587-026-01179-y

Keywords: TERT, telomerase, aging, healthspan, epigenetics, mitochondria, inflammation, cancer risk

Imagine that you are in your sixties or seventies, and on a brisk walk. Your muscles contract, setting off small waves of calcium and other signaling molecules. In response, your skeletal muscle cells secrete a host of myokines into your bloodstream—molecules such as interleukin-6 (IL-6) and irisin. Meanwhile, your adipose tissue, sensing metabolic demands, releases adipokines that fine-tune insulin sensitivity. Your liver, stirred by changes in blood flow and metabolic substrates, sends out hepatokines such as fibroblast growth factor 21 (FGF21). And your bones, subjected to the forces of gravity and muscle tension, secrete osteocalcin or other osteokines that preserve skeletal integrity. Even your brain—through glial cells or neurons—contributes neurokines that bolster synaptic plasticity. All these exerkines then travel through the bloodstream, coordinating with different organs, collectively pushing back against the harmful effects of age-related stress and inflammation.

It is well known that aging coincides with a series of systemic changes—reduced muscle mass (sarcopenia), diminishing bone density (osteoporosis), elevated inflammation (“inflammaging”), and a decline in mitochondrial quality. The danger is that these changes feed into each other, leading to a spiraling loss of vitality. But the exerkines triggered by regular physical activity can break this vicious cycle. For instance, certain exerkines promote a shift away from chronic inflammation by boosting the production of anti-inflammatory mediators like interleukin-10 (IL-10) and restricting pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α). Others enhance the oxidative capacity of skeletal muscle, reducing the accumulation of reactive oxygen species (ROS) and preventing mitochondrial decay—major contributors to cellular dysfunction in older adults.

Scientists have begun to pinpoint precisely how exerkines exert these protective effects. One factor is the well-known molecule IL-6, which can exhibit pro-inflammatory behavior in certain contexts but acts as an anti-inflammatory signal during and immediately after exercise. Another is irisin, a hormone-like factor that helps convert white adipose tissue into a more metabolically active “beige” fat, raising one’s resting energy expenditure while improving insulin sensitivity and metabolic health. Meanwhile, fibroblast growth factor 21 (FGF21), secreted mainly by the liver, exerts beneficial effects on glucose control and lipid metabolism, thus lowering one’s vulnerability to type 2 diabetes. Myostatin, once considered only a negative regulator of muscle growth, has emerged as a possible modulator of tumor suppression. Apelin, another exerkine, fosters the health of both bone and muscle tissue, helping older bodies withstand the rigors of daily life. And in the brain, molecules like clusterin or glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) can dampen inflammation and shore up neural plasticity, safeguarding cognition in older adults.

At first, it may sound like an astonishing synergy: how can the same physical movement help the heart, bones, muscles, immune system, and even the brain? But the body’s architecture is deeply interconnected, and exerkines serve as the biochemical messengers that tie all these benefits together. Perhaps the clearest example is skeletal muscle, the largest organ by mass in most people, which rapidly communicates with other tissues during a workout. The molecular signals it emits—the myokines—can travel to the liver to promote better fat oxidation, or to the brain to encourage synaptic plasticity. They may also act on the immune cells, fine-tuning the balance between pro-inflammatory and anti-inflammatory signaling. Likewise, adipose tissue secretes adiponectin, which fosters fatty acid oxidation and reduces insulin resistance in muscle and liver, while also modulating inflammatory processes system-wide. This level of cross-organ “conversation” explains why a simple brisk walk or a few sets of resistance exercises per week can lower the risk of so many age-related conditions—from cardiovascular disease and type 2 diabetes to osteoporosis and some cancers.

Given the multiplicity of exerkines, it should be no surprise that different forms of exercise generate distinct benefits. The recommendation for older adults, proposed by various international guidelines, generally includes a combination of resistance training, aerobic exercise, and balance activities. Resistance or weight training stimulates muscle hypertrophy and strength gains, spurring the release of exerkines that specifically promote muscle repair and anabolism. Aerobic exercises like walking, jogging, or cycling, at intensities around 55–70% of maximum heart rate, are associated with improved cardiovascular function, higher levels of beneficial cytokines such as IL-10, and better glycemic control. Balance and flexibility exercises, such as yoga and tai chi, are no less important; they may not generate as high an acute exerkine surge as intense resistance training or cardio, but they do help preserve neuromuscular coordination and reduce the risk of falls—a critical factor in healthy aging.

One of the cornerstones of exerkine research is the notion that improving mitochondrial function is a central mechanism of “exercise as medicine.” With age, mitochondria in cells become less efficient at producing ATP (adenosine triphosphate), and they accumulate oxidative damage. Exercise can mitigate this by increasing the expression of key enzymes like glutathione peroxidase (GPx), superoxide dismutase (SOD), and heme oxygenase-1 (HO-1), which help neutralize free radicals. ROS no longer run rampant, so the negative feedback loop leading to further mitochondrial damage is dampened. Meanwhile, exerkines promote the production of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a major driver of mitochondrial biogenesis. As a result, older individuals who engage in physical activity can regenerate healthier mitochondria, thus powering their cells more effectively. The payoff is less cellular senescence, improved nutrient sensing, and often a reduction in chronic inflammation.

It is important to note that the synergy between exercise and exerkines extends into domains like cognitive function. Regular training fosters a rise in brain-derived neurotrophic factor (BDNF), a neurotrophin essential for neuronal survival, synaptic plasticity, and hippocampal neurogenesis. This helps guard against the cognitive deficits associated with disorders such as Alzheimer’s disease. Some exerkines, such as glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) and platelet factor 4 (CXCL4), have also been implicated in hippocampal neurogenesis, encouraging the generation of new neurons and reversing certain aspects of age-related mental decline. These discoveries resonate strongly with observational data showing that physically active older adults frequently show slower cognitive decline and lower incidence of neurodegenerative conditions.

For those concerned about type 2 diabetes, exercise again steps in with an exerkine-mediated strategy. Muscle contraction not only draws glucose into cells via transporters like GLUT4, it also triggers the release of certain hepatokines from the liver and adipokines from fat that normalize blood sugar levels. FGF21, for instance, fosters insulin sensitivity, while HSP72 (heat shock protein 72) can prevent misfolded protein accumulation in pancreatic beta cells. Even short bursts of activity can drive these beneficial changes. Though many older people worry about whether they can safely engage in vigorous workouts, the research points to moderate, consistent habits—like walking daily or lifting light weights multiple times a week—as enough to catalyze these systemic benefits.

Another striking area of discovery is the way exerkines appear to influence bone health. Osteocalcin, produced by bone in response to the mechanical load from weight-bearing exercise, helps maintain bone mineral density and appears to have metabolic functions that extend beyond bone. It may, for example, improve insulin sensitivity. Meanwhile, molecules such as TGF-β1 and apelin, also upregulated by exercise, can help coordinate bone formation and muscle mass. For older adults whose bones grow increasingly fragile, these factors are a ticket to reduced fracture risk and better musculoskeletal resilience. In some scenarios, the synergy between osteokines and myokines can help accelerate bone healing after injury or surgery, a tremendous boon for those in advanced age.

Add to this the remarkable possibility that exerkines carry at least some anti-cancer properties, and exercise’s significance in health management gains still more luster. Myostatin, ironically known for suppressing muscle growth, has recently been linked to anti-tumor functions in certain tissues, possibly by dampening pathways that drive unchecked proliferation. Irisin, once studied for its effect on adipose tissue browning, also shows promise as an anti-tumor agent in preclinical models, often by boosting the immune system’s detection of malignant cells or by altering local inflammatory signals that help tumors thrive. Even though these studies are preliminary, they open an exciting dimension of research: perhaps a consistent exercise routine could lower both the risk of developing cancer and, in some cases, slow progression for those who already have it.

Despite the avalanche of positive evidence, we must tread carefully. Not all forms or intensities of exercise deliver uniform exerkine responses. Overtraining—exercising too vigorously or too frequently—can create oxidative stress or immune suppression, especially in older individuals who may have other comorbidities. The goal, therefore, is moderation and personalization: designing a plan that taps into the beneficial exerkine output without overwhelming the body’s capacity to recover. Many new areas of research revolve around “exercise mimetics,” compounds that mimic the effect of exerkines by targeting the same molecular pathways. For individuals too frail to exercise adequately, such compounds could theoretically provide the health benefits of a workout. But the nuance is that exercise is not merely a pill to be replaced; it sets in motion large-scale mechanical, neural, and metabolic processes that may not be fully replicated by a single compound or cocktail.

What will the future hold for this intriguing domain of exerkines and anti-aging strategies? One possibility is that health practitioners will monitor exerkine levels in the bloodstream to gauge whether an older adult’s exercise regimen is truly effective. Another is that gene- or cell-based therapies could selectively increase expression of beneficial exerkines, or block “rogue” molecules that hamper healthy aging. As more is uncovered about how these molecules act and interact, a new generation of geriatric medicine could arise, leveraging exerkines to combat conditions as diverse as Alzheimer’s, frailty, and diabetes. Pharmacologists already see exerkines as potential “druggable” targets. For instance, if we can harness the browning effect of irisin safely, we might treat obesity without radical changes in diet. If we can modulate clusterin or BDNF effectively, we might slow cognitive decline. Conversely, controlling overactive inflammatory exerkines in certain autoimmune settings might stave off age-associated autoimmune conditions.

Yet, in the midst of all these futuristic innovations, the core message remains clear: regular movement, even in modest doses, is already our best bet for “turning on” these beneficial exerkines. Where certain pharmaceutical avenues may take years to become safe and widely available, everyday exercise is accessible now, with little risk and abundant upside. Medical experts emphasize that older adults should combine strategies: build in some resistance training to preserve muscle mass and bone density, incorporate aerobic exercise to bolster cardiovascular and metabolic function, and do balance activities to reduce fall risk and maintain neural reflexes. These are not complicated tasks, but the molecular payoffs—in the form of exerkine release—can be profound.

Ultimately, the story of exercise-induced exerkines is one of the most compelling examples of how our bodies are designed for movement, and how that movement orchestrates a symphony of positive biological signals. By activating these signals through conscious, consistent activity, we tap into a powerful, evolution-built mechanism that defends us against the degradations of time. Gone are the days when we could think of exercise merely as a means to burn calories. Instead, each session of walking, resistance training, or mindful balance exercises sets off thousands of molecular changes that can be harnessed to keep us healthier for longer. It is a powerful illustration that our biology wants us to move, and in moving, we coax our cells to produce molecules that can keep the ravages of age at bay.

As researchers continue to refine our understanding, we may see more targeted advice on the most effective exercise “doses,” frequencies, and intensities for stimulating beneficial exerkines. We may also see novel interventions that help older adults overcome barriers to physical activity, from wearable technology that tracks functional movement patterns to community programs aimed at delivering personalized exercise regimens. If further breakthroughs arrive with safe and effective exercise mimetics, so much the better. Yet for now, the basic science underscores a unifying conclusion: exercise remains one of our most potent forms of preventive medicine, not just for the muscle and cardiovascular advantages, but for the invisible molecular crosstalk that might very well determine how gracefully and how long we age.

Subject of Research: Exercise and Exerkines in Anti-Aging and Disease Prevention
Article Title : Exercise and Exerkines: Mechanisms and Roles in Anti-Aging and Disease Prevention
News Publication Date : February 2025
Article Doi References : https://doi.org/10.1016/j.exger.2025.112685
Keywords : Exerkines, Anti-aging, Exercise Physiology, Mitochondrial Function, Muscle Mass, Inflammaging, Cognitive Decline, Metabolic Homeostasis, Bone Density